GNPDA2 — The Hexosamine Pathway's Weight Regulator
rs10938397 sits in a regulatory region near GNPDA2 (glucosamine-6-phosphate
deaminase 2) on chromosome 4p12 and was identified in the landmark
GIANT consortium GWAS11 GIANT consortium GWAS
Willer et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nature Genetics, 2009
as one of six new obesity-associated loci, with a per-allele BMI increase of
0.19 kg/m² and a combined p-value of 3.4×10⁻¹⁶ across 81,758 individuals.
The G allele is the risk allele.
The Mechanism
GNPDA2 encodes an allosteric enzyme that catalyzes the reversible conversion
of D-glucosamine-6-phosphate to D-fructose-6-phosphate and ammonium. This
reaction sits at a critical junction: it opposes the action of GFAT
(glutamine-fructose-6-phosphate amidotransferase22 glutamine-fructose-6-phosphate amidotransferase
The rate-limiting enzyme feeding into the hexosamine biosynthesis pathway, which produces UDP-GlcNAc for protein O-GlcNAcylation and cellular signaling),
functioning as a brake on hexosamine flux. The hexosamine pathway is a
nutrient sensor — its output, UDP-GlcNAc, modifies proteins and influences
insulin signaling, gene expression, and cellular metabolism in proportion to
glucose availability.
GNPDA2 is
highly expressed in the hypothalamus33 highly expressed in the hypothalamus
Specifically in the arcuate nucleus (ARC), dorsomedial hypothalamus (DMH), lateral hypothalamic area (LHA), and paraventricular nucleus (PVN)
and in adipose tissue, with lower expression in muscle and liver. A
2021 functional study44 2021 functional study
Central administration of a GNPDA2 antagonist into the third ventricle of rats; Frontiers in Nutrition, 2021
showed that central GNPDA2 inhibition does not alter food intake or body
weight — ruling out appetite as the primary mechanism — but causes glucose
intolerance during an intraperitoneal glucose challenge without changing
insulin levels. This positions GNPDA2 as a central regulator of glucose
handling, with effects mediated through insulin sensitivity rather than
insulin secretion or appetite drive.
In adipose tissue, the picture is complementary: a
2019 study55 2019 study
Wu et al. GNPDA2 Gene Affects Adipogenesis and Alters the Transcriptome Profile of Human Adipose-Derived Mesenchymal Stem Cells. International Journal of Endocrinology, 2019
demonstrated that overexpression of GNPDA2 in human adipose-derived
mesenchymal stem cells enhances lipid droplet accumulation and adipocyte
differentiation, while knockdown suppresses adipogenesis. The transcriptome
changes affected genes involved in fatty acid metabolism, lipid modification,
and glucose homeostasis.
The Evidence
The association is among the most robustly replicated in obesity genetics.
The original GIANT discovery in
32,000 European subjects with replication in 59,000 more66 32,000 European subjects with replication in 59,000 more
Willer et al. Nature Genetics, 2009
was confirmed in a 249,796-individual meta-analysis
(Speliotes et al. Nature Genetics, 201077 Speliotes et al. Nature Genetics, 2010)
and the largest BMI GWAS to date,
339,224 individuals88 339,224 individuals
Locke et al. Nature, 2015.
In a Danish cohort of 18,014 adults, the G allele was associated with
OR 1.15 for obesity (p = 1.1×10⁻⁴)99 OR 1.15 for obesity (p = 1.1×10⁻⁴)
Sandholt et al. Studies of Metabolic Phenotypic Correlates of 15 Obesity Associated Gene Variants. PLOS ONE, 2011,
BMI increase of 0.28 kg/m² per allele, and a 0.61 cm increase in waist
circumference. Nominal associations with fasting insulin and
HOMA-IR1010 HOMA-IR
Homeostatic Model Assessment of Insulin Resistance — a measure of insulin sensitivity derived from fasting glucose and insulin
were also observed but did not survive correction for multiple testing.
In Mexican children, the association was stronger:
OR 1.30 for obesity (p = 1.34×10⁻³)1111 OR 1.30 for obesity (p = 1.34×10⁻³)
Mejia-Benitez et al. BMC Medical Genetics, 2013.
A Chinese study found the G allele associated with increased BMI, fat mass
percentage, and waist-to-height ratio in children, with effects varying by
sex and pubertal stage.
The G allele frequency is approximately 0.43 in Europeans (risk allele frequency 41% in the Danish cohort) — making this a very common variant. The GG genotype, carrying the highest risk, occurs in ~18% of Europeans.
Interactions
rs10938397 contributes to a polygenic obesity risk profile alongside FTO (rs9939609), MC4R (rs17782313), TMEM18 (rs6548238), and NEGR1 (rs2815752). GWAS evidence indicates these effects are additive: carrying risk alleles at multiple loci compounds the BMI increase, and a person with risk alleles at GNPDA2 plus FTO or MC4R faces a higher cumulative genetic burden than at either locus alone. No synergistic (multiplicative) interaction has been documented among these loci — their combined effect is the sum of their individual contributions.